ARAVA Drug Patent Profile

When do Arava patents expire, and what generic alternatives are available?

Arava is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in ARAVA is leflunomide. There are seven drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leflunomide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Arava

A generic version of ARAVA was approved as leflunomide by APOTEX on September 13^th, 2005.

Summary for ARAVA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,593
Drug Prices:	Drug price information for ARAVA
What excipients (inactive ingredients) are in ARAVA?	ARAVA excipients list
DailyMed Link:	ARAVA at DailyMed

See drug prices for ARAVA

Pharmacology for ARAVA

Drug Class

Antirheumatic Agent

US Patents and Regulatory Information for ARAVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998	AB	RX	Yes	No
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998	AB	RX	Yes	Yes
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998		RX	Yes	Yes

Expired US Patents for ARAVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998

EU/EMA Drug Approvals for ARAVA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Zentiva k.s.	Leflunomide Zentiva (previously Leflunomide Winthrop)	leflunomide	EMEA/H/C/001129Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	no	no	no	2010-01-08
Ratiopharm GmbH	Leflunomide ratiopharm	leflunomide	EMEA/H/C/002035Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	yes	no	no	2010-11-28
medac Gesellschaft für klinische Spezialpräparate mbH	Leflunomide medac	leflunomide	EMEA/H/C/001227Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	yes	no	no	2010-07-27
Sanofi-aventis Deutschland GmbH	Arava	leflunomide	EMEA/H/C/000235Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Authorised	no	no	no	1999-09-02
Teva B.V.	Repso	leflunomide	EMEA/H/C/001222Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a ‘disease-modifying antirheumatic drug’ (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Withdrawn	yes	no	no	2011-03-14
Teva Pharma B.V.	Leflunomide Teva	leflunomide	EMEA/H/C/002356Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.	Withdrawn	yes	no	no	2011-03-10

International Patents for ARAVA

See the table below for patents covering ARAVA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	96669
Mexico	8403	PROCEDIMIENTO PARA LA PREPARACION DE (4-TRIFLURO METIL)-ANILIDA DE ACIDO 5 METIL-ISOXASOL-4-CARBOXILICO.
Australia	529341
Israel	80149	PHARMACEUTICAL COMPOSITIONS CONTAINING TOLUIDIDE DERIVATIVES AGAINST GRAFT-VERSUS-HOST DISEASES AND AUTOIMMUNE DISEASES
Japan	H0729918
South Korea	840001559
Japan	S5583767	ISOXAZOLE DERIVATIVE AND ITS MANUFACTURE

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Arava

Last updated: July 29, 2025

Introduction

Arava (leflunomide) is an immunomodulatory medication primarily indicated for the treatment of rheumatoid arthritis (RA). Approved by the FDA in 1998, it belongs to the class of disease-modifying antirheumatic drugs (DMARDs). Its market stability hinges on several factors—clinical efficacy, competition, patent status, healthcare policies, and emerging biosimilars. This report delineates the current market landscape, growth drivers, challenges, and future financial projections for Arava.

Market Overview and Demand Drivers

The global rheumatoid arthritis therapeutics market has experienced consistent growth, driven by rising prevalence, aging populations, and a shift toward targeted therapies. According to the CDC, RA affects approximately 1.3 million Americans, with similar prevalence rates worldwide, creating sustained demand for DMARDs like Arava [1].

Arava's mode of action as a pyrimidine synthesis inhibitor offers an alternative for patients intolerant or refractory to methotrexate, increasing its clinical utility. Its well-documented safety profile and chronic use align with healthcare providers' preference for long-term management options.

Market Dynamics

1. Competitive Positioning and Market Share

Arava's primary competitors include methotrexate, hydroxychloroquine, sulfasalazine, and newer biological agents such as TNF inhibitors (adalimumab, etanercept) and Janus kinase inhibitors (tofacitinib). While biologics dominate the RA pharmaceutical landscape due to higher efficacy, oral DMARDs like Arava hold significant niche appeal, especially for early-stage RA and cost-sensitive markets.

The patent for Arava expired in 2019, opening the door to biosimilar entries and generic alternatives. Although leflunomide's chemical compound is unpatented post-2019, clinical and patent protection for formulation modifications or combination therapies could impact its market retention.

2. Pricing and Reimbursement Landscape

Leflunomide's generally favorable cost profile makes it attractive in hospitals and outpatient settings, especially in countries with strict drug reimbursement policies. Cost-effectiveness analyses favor Arava in specific patient segments. Nevertheless, biosimilar competition and payer negotiations influence pricing strategies and market access.

3. Regulatory Environment and Patent Considerations

The loss of patent exclusivity in key markets has subjected Arava to biosimilar competition, exerting downward pressure on prices and market share. However, regulatory hurdles and patent litigation can delay biosimilar penetration, temporarily sustaining Arava’s revenues.

4. Regional Market Variability

Emerging markets in Asia, Latin America, and Eastern Europe demonstrate growing RA treatment adoption. Cost considerations strongly influence therapy choices, often favoring established, affordable drugs like Arava. In contrast, mature markets prioritize biologics but still rely on DMARDs as first-line or adjunct options.

Financial Trajectory

1. Historical Revenue Trends

Between 2010 and 2018, Arava’s annual global sales hovered around $300-$400 million, reflecting its stable yet plateauing profile. Post-patent expiry, a decline in revenue likely ensued due to biosimilar competition and generic options.

2. Future Revenue Projections

Based on market analyses, Arava's revenue is projected to decline by approximately 5-7% annually over the next five years due to biosimilar erosion and generics. However, this decline could be mitigated through strategic marketing, formulation innovations, or combination therapies.

A conservative estimate suggests that by 2025, global sales could dwindle to approximately $150-$200 million. Conversely, a focused effort to penetrate underserved markets could stabilize revenues in select regions.

3. Impact of Biosimilar Entry

The advent of biosimilars for RA biologics has shifted the therapeutic landscape, indirectly affecting non-biologic DMARDs like Arava. Nevertheless, in markets where biosimilars are less accessible or financially feasible, Arava retains a niche. Price competition among biosimilars may indirectly influence Arava’s market revenues through reimbursement policies.

4. Strategic Opportunities for Growth

Potential growth avenues include:

• Combination Therapy: Developing fixed-dose combinations with other DMARDs or biologics.
• Formulation Innovations: Extending formulations for better adherence.
• Specialty Indications: Exploring off-label uses or emerging indications such as psoriatic arthritis.
• Market Expansion: Targeted marketing in developing economies.

Challenges and Risks

The primary challenges include biosimilar and generic competition, evolving treatment guidelines favoring biologics and JAK inhibitors, and regulatory hurdles. Additionally, safety concerns, such as hepatotoxicity and teratogenic risks, necessitate robust patient monitoring, impacting marketability.

Conclusion: Market Outlook

Arava's market dynamics are shaped by patent expirations, competitive landscape shifts, and regional preferences. While revenues are projected to decline steadily, targeted strategies leveraging geographic expansion, formulation advances, and combination regimens could sustain its relevance.

The financial trajectory underscores the importance of adaptation amidst evolving RA treatment paradigms. Pharmaceutical companies must monitor biosimilar developments and invest in differentiated value propositions to optimize revenues.

---

Key Takeaways

• Stable but declining market: Arava's revenues face a gradual decline primarily due to biosimilar and generic competition post-patent expiry.
• Regional variability: Emerging markets offer growth opportunities owing to cost sensitivity and less biosimilar penetration.
• Strategic differentiation: Innovating formulations and exploring combination therapies can buffer revenue erosion.
• Competitive landscape: The rise of biologics and JAK inhibitors shifts treatment paradigms, marginalizing older DMARDs like Arava.
• Pricing and reimbursement strategies: Cost-effective positioning remains vital, especially in regions with constrained healthcare budgets.

---

FAQs

1. How has patent expiry impacted Arava’s market share?
Patent expiration in 2019 facilitated biosimilar and generic entry, leading to increased price competition and a decline in Arava’s market share, especially in mature markets.

2. Are there emerging indications that could revitalize Arava’s market?
Potential off-label uses and combination therapies could expand Arava’s application, but current evidence is limited, and regulatory approvals are necessary for such indications.

3. How do biosimilars of biologic RA drugs affect Arava?
Biosimilars primarily impact biologic therapies; however, the growing preference for biologics over traditional DMARDs indirectly pressures older drugs like Arava to lower prices or innovate.

4. What regions are most favorable for Arava’s future growth?
Emerging economies with limited biosimilar penetration and cost-sensitive healthcare systems present the most promising regions for Arava’s sustained use.

5. What strategic actions can pharmaceutical companies take to extend Arava's market relevance?
Investing in formulation improvements, exploring combination therapies, and expanding into underserved markets can help mitigate revenue decline.

---

References

[1] Centers for Disease Control and Prevention (CDC), “Rheumatoid Arthritis (RA),” 2022.